- Resistance training as a treatment for older persons with peripheral artery disease: A
 systematic review and meta- analysis
- 3 Parmenter: Resistance training for peripheral artery disease.
- 4 Parmenter, BJ¹ PhD. Mavros, Y² PhD. Ritti-Dias, RM³ PhD. King, S⁴ PhD. and Fiatarone
 5 Singh MA^{2, 5} MD.
- ¹ Department of Exercise, Physiology, School of Medical Sciences, Faculty of Medicine,
 UNSW Sydney, NSW, Australia
- 8 ² Physical Activity, Lifestyle, Ageing and Wellbeing Faculty Research Group, Faculty of
- 9 Health Sciences, University of Sydney, NSW, Australia
- ³ Rehabilitation Sciences Post-graduate Program, Universidade Nove de Julho, São Paulo, SP,

11 Brazil

- ⁴ Sport, Health and Exercise Sciences, University of Hull, Hull, United Kingdom.
- ⁵ Sydney Medical School, USYD, NSW, Australia; Hebrew SeniorLife and Jean Mayer
- 14 USDA Human Nutrition Center on Aging at Tufts University, Boston, MA, USA

Address for Correspondence to:	Dr Belinda Parmenter
	Department of Exercise Physiology
	School of Medical Science
	University of NSW
	Sydney, NSW, Australia, 2052
	Address for Correspondence to:

- 20 Telephone: +61 2 9385 8313
- 21 Email: <u>b.parmenter@unsw.edu.au</u>
- 22

This article has been accepted for publication in British Journal of Sports Medicine. The definitive

- copyedited, typeset version Parmenter, B. J., Mavros, Y., Ritti Dias, R., King, S., & Fiatarone Singh, M.
 (2019). Resistance training as a treatment for older persons with peripheral artery disease: A systematic
- 24 (2019). Resistance training as a treatment for older persons with peripheral artery disease: A s review and meta-analysis. British journal of sports medicine, 1-11. https://doi.org/10.1136/
- ²⁵ bisports-2018-100205 is available online at : http://bism.bmj.com

1 Abstract

Objective: Resistance training (RT) improves walking ability in persons with peripheral artery disease. We conducted a meta-analysis of randomised controlled trials (RCTs)
investigating the effect of RT on peripheral artery disease (as measured by walking ability).

5 **Design:** We included RCTs that investigated the effect of RT on treadmill and/or 6-minute 6 walk (6-MWT) distances. RT intensity was assessed according to ACSM guidelines by 1RM 7 or Rating of Perceived Exertion (RPE). Standardised mean (SMD) and mean differences 8 (MD) were calculated using a random effects inverse variance model. Heterogeneity and bias 9 were assessed using Revman 5.3. Meta-regression and meta-anova were performed as 10 moderator analyses.

Data Sources: Databases (Medline, Embase, Web of Science, Cinahl, Google Scholar) were
 searched until July 2018.

Results: Fifteen trials isolated RT; 7 trials compared RT to aerobic exercise. We analysed 13 14 826 patients (n=363 completing RT), mean age 67.1 ± 3.8 years. Training ranged from lowhigh intensity; 2-7 times per week for 17±7weeks, with a mix of upper, lower or whole body 15 training. Overall RT significantly improved constant load treadmill claudication onset 16 (COD)(SMD 0.66[0.40, 0.93], p<0.00001) and total walking distance (WD)(SMD 0.51[0.23, 17 0.79], p=0.0003), progressive treadmill COD(SMD 0.56[0.00, 1.13], p=0.05) and total 18 WD(SMD 0.45[0.08, 0.82], p=0.02) and 6-MWT COD(MD 82.23m[40.91, 123.54], 19 p<0.0001). Intensity played a role in improvements, with high intensity training yielding the 20 greatest improvement (p=0.02). 21

Conclusions: RT clinically improved treadmill and flat ground walking ability in persons with PAD. Higher intensity training was associated with better outcomes. Our study makes a case for clinicians to include high intensity lower body RT in treatment of peripheral artery disease.

26 **PROSPERO Systematic Review Registration #:** CRD42017081184

27

28

29

Summary Points: What is already known?

- Interval walking is the current gold standard treatment for PAD.
- Resistance training can improve walking ability in persons with peripheral artery disease; there has been no previous synthesis of the literature.

What are the new findings?

- Resistance training improves both flat ground and graded treadmill walking ability in persons with peripheral artery disease, by a clinically meaningful extent.
- Better results were related to higher intensity training.

1

2 Introduction

3 Peripheral artery disease (PAD) is an atherosclerotic disease affecting the arteries of the 4 periphery, most commonly the aorta and iliac arteries, and the arteries of the lower limbs and 5 it affects over 200 million people worldwide(1). Although some people may be 6 asymptomatic, others may present with intermittent claudication symptoms. Claudication, a 7 fatigue, cramp, discomfort or pain in the lower limb, is a symptom of reduced muscle blood supply(2). Peripheral artery disease eventually denervates lower limb muscle fibres(3), which 8 9 causes muscle weakness, (4, 5) atrophy (6, 7) and altered lower limb biomechanics (8-10). This 10 limits walking ability and impairs quality of life in this population.

11

Current treatment guidelines for peripheral artery disease (PAD) recommend interval walking 12 13 as the first line therapy, along with other modes of aerobic exercise and resistance training (RT) as an adjunct treatment for the condition(2, 11). In addition, some guidelines omit the 14 mode of exercise and only provide prescriptive elements of supervision, frequency, duration 15 16 and length of program(12). Whilst intermittent walking is an effective exercise prescription for people who can complete it, people with severe intermittent claudication may struggle to 17 take part due to chronic diseases and conditions that limit the ability to walk or be physically 18 active (e.g. chronic obstructive pulmonary disease, obesity, arthritis, amputation or 19 20 cerebrovascular disease with stroke(13)). Furthermore, people with intermittent claudication 21 have intense pain with walking(14, 15). Some people have low confidence in their walking ability, and believe the pain induced by it can be harmful(14, 16). These factors might lead to 22 increased sedentary behaviour(17), accelerated functional decline(18), reduced aerobic 23 24 capacity or cardiorespiratory fitness and reduced muscle strength and endurance (19-22), all impairing walking ability further and ultimately reducing quality of life(23). 25

1

2 RT does not typically cause claudication pain(24-28), and improves cardiovascular disease 3 risk factors(29-35) and aerobic capacity and attenuates functional decline, yet is typically 4 recommended only as an adjunct to aerobic exercise for the treatment of PAD(2, 36). Therefore, we conducted a systematic review and meta-analysis on randomised controlled 5 trials (RCTs) using RT as an intervention for persons with PAD, with walking ability as an 6 7 outcome. We aimed to identify whether or not RT is effective at improving walking ability in this population by analysing the effect of RT compared to usual care or aerobic exercise 8 9 training on six minute walk (6-MWT) distance and treadmill walking. Primary outcomes included claudication onset distance (COD) and total walking distance (WD) for all walking 10 tests. We also aimed to identify whether there are any moderators associated with changes in 11 walking ability. For the purpose of this review, RT included any structured body weight, 12 machine and/or free weight-based RT where muscles contracted against some form of 13 14 external resistance or immovable object/surface.

15

16 Methods

This review was registered with PROSPERO on the 8th December 2017 CRD42017081184 17 18 Five electronic databases (Ovid Medline/PubMed, Scopus/Web of Science, PEDro, EMBASE and Cochrane Library) were searched from earliest record until July 2018. Search 19 terms used include (peripheral vascular or claudica* or peripheral arter*) AND (exer* or 20 21 resist* or weightlifting or strength or musc* exercise or circuit or endurance) AND (random* 22 or control*). One study author (BP) ran the search and uploaded the search results into one 23 Endnote database. After excluding duplicates one author (BP) reviewed all titles and abstracts for possible inclusion. Any full papers that were retrieved for evaluation were then screened 24 25 by two authors for inclusion (BP and YM). Any disputes were settled by a third author

(MFS). The reference lists of eligible papers were reviewed to identify other relevant studies
 and recent related systematic reviews were consulted to identify any additional studies that
 may have been missed.

4

5 Studies were included if they were a randomised controlled trial on any persons with diagnosed PAD who took part in a RT intervention for \geq 4 weeks, with walking ability 6 7 measured via treadmill protocols and/or the six minute walk test (6-MWT) distance as an 8 outcome. For the purpose of this review, muscular fitness was defined according to the 9 American College of Sports Medicine (ACSM) where it is used as a collective term for 10 muscular strength, power and endurance(37). Muscular fitness can be improved by a strength exercise training program, where a movement is performed that causes the muscles to 11 12 contract against an external resistance with the expectation of increases in strength, tone, mass and/or endurance(38). Equipment used can include free weights, machines with stacked 13 14 weights, pneumatic resistance, resistance bands, springs or body weight. To be included in this review RT must have included multi-joint or compound exercises (e.g., chest press, 15 shoulder press, pull downs, rows, leg press, squats, deadlifts), or single joint exercises 16 17 targeting major muscle groups (e.g., bicep curls, triceps extensions, quadriceps extensions, leg curls, calf raises). Studies that included exercises targeting the core muscles (e.g., planks, 18 bridges) were also included. Training programs could be circuit type in nature, where clear 19 exercise:rest intervals were defined, or a more traditional form of RT where reps and sets 20 were completed without specified set time and recovery between sets was 2-3 minutes. To be 21 22 labelled progressive, the resistance exercise must have been progressive by design, in that the absolute workload prescribed increased over time(38). The workload increase may have been 23 achieved by greater forces used, number of exercises, volumes (sets/reps), frequencies of 24 training, or relative intensities of the loads or maximal effort prescribed. 25

2 As there is a dose-response association between the volume of exercise and some 3 outcomes(38), RT volume was defined using sets x repetitions x number of days per 4 week(37). Intensity was also defined according to ACSM(39) where: 5 • $\geq 85\%$ of 1 repetition maximum (1RM) or Rate of Perceived Exertion(40) (RPE) ≥ 18 6 is very high, near maximal or maximal; • 70-84% of 1 RM or RPE 14-17 is high; 7 • 50-69% of 1 RM or RPE 12-13 is moderate; 8 9 • 30-49% 1RM or RPE 9-11 is light; • <30% 1RM or RPE<9 is very light. 10 11 12 To be included studies must have compared the intervention to the current unsupervised walking guidelines (usual medical care), or a supervised aerobic exercise training program. 13 14 Outcomes to be assessed included COD, defined as the moment in which claudication pain

starts, and total WD, defined as the maximal walking distance obtained from a constant load

16 and/or graded treadmill test and/or 6-MWT. A secondary outcome of muscle strength was

assessed for trials that included this measure. Trials were excluded if they combined a RT

18 intervention with an aerobic exercise intervention and the effects of RT could not be isolated;

19 or if they were completed on animals, or not published in English in a peer-reviewed journal

20 or thesis. Trials were also excluded if asymptomatic patients were grouped with symptomatic

21 patients with PAD and the symptomatic patients were unable to be isolated. Data was

22 extracted by one author (BP) on to pre-piloted data forms. Authors were contacted for

23 missing data.

24

1

25 <u>Risk of Bias</u>

Risk of bias of the included studies was assessed using the Cochrane Collaboration's tool for 1 assessing risk of bias. Eight domains of potential bias were assessed (Supplementary Table 2 3 1): including sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; complete outcome data; free of selective outcome 4 reporting, baseline similarity and ITT data analyses. Scores were summed across all 8 5 6 domains to give a total score of risk bias for each study, with a possible range of 1-8. Studies 7 with a higher score were deemed to be of higher quality, and therefore lower risk of bias. 8 However, rather than focusing on just the scores, the quality of each study was assessed by 9 whether or not points were given for individual quality criterion. With randomisation already being a necessary criterion, studies that have points allocated for randomised sequence 10 generation, allocation concealment, blinding of participants, blinding of outcome assessors, 11 12 and intention to treat analysis and were free of any other bias were deemed higher quality and therefore lower risk of bias. 13

14

15 Data Extraction

16 Walking distances analysed were the mean difference (MD) between pre- and post-group 17 data which was calculated by subtracting baseline from post values for both the control and intervention groups. Data required was the individual group sample size, mean change and 18 19 standard deviation (SD) or 95% confidence interval of the change score and/or within group p-value. When the confidence interval or SD was not available actual p-values for pre/post 20 21 intervention change were used. If only the level of significance was available, we used 22 default p-values where p<0.05 becomes p=0.049, p<0.001 becomes p=0.0099 and p=not 23 significant becomes p=0.051. Values were taken from baseline measures, and then at the 24 time-point closest to the end of the intervention period. For studies that contributed multiple comparisons (e.g., one control group and two interventions groups(41)), the control group
 data were evenly divided into two smaller groups.

3

4 Data Synthesis

5 A narrative synthesis regarding participant characteristics and study interventions was 6 completed. Aggregate data were used in the analyses. Mean difference (MD) and 95% 7 Confidence Interval (CI) was calculated for the 6-MWT measures (reported in meters) and to 8 account for any differences in testing protocols, SMD and 95% CI was calculated for the 9 treadmill WD using the Cochrane RevMan calculator(42) in Revman version 5.3 (Nordic Cochrane Centre, Denmark). MD was unable to be calculated for constant and progressive 10 load treadmill protocols due to the difference in protocols used across trials (i.e., some 11 12 constant load protocols ran at different speeds and/or grades to other constant load protocols, and vice versa for progressive grade protocols). If enough data were provided then a 13 14 quantitative synthesis was completed on each of the outcomes using an inverse variance, 15 random effects analysis. Both statistical and clinical meaningfulness of outcomes were 16 characterized. Statistical significance of SMDs was inferred if the CIs did not cross zero. 17 Clinical meaningfulness of the MDs were interpreted such that a 50 m improvement in 6-MWT distance was considered to be the lower threshold of a clinically important difference 18 in this cohort(43), as this improvement is associated with a reduction in cardiovascular 19 20 mortality.

21

22 <u>Moderator Analysis</u>

The significance of any heterogeneity identified was examined using the Cochran's Q (χ²)
test with p<0.05 indicating significant heterogeneity. Interpretation of heterogeneity was
based on Cochrane recommendations(41) using Higgins I², with scores ranging from 0 to

1 100%. A cut-off of 40% was used to proceed to moderator analysis if 3 or more studies were present to help identify sources of heterogeneity in the overall meta-analysis. Moderators 2 assessed included age, ankle brachial index, frequency, intensity, RT method, number and 3 4 area of exercises, total repetitions, program length, progression and study quality. Univariate meta-regression analyses were used to assess the influence of continuous variables such as 5 6 frequency, length of intervention, duration of session on walking ability. Meta-anova was 7 completed on categorical variables such as intensity or location of training. Metaregression/anova analyses were completed with a random intercept, fixed slopes model using 8 9 "Wilson's SPSS macro(44)" and SPSS Statistics for Windows, Version 24.0 (IBM Corp, Armonk, New York, USA). For studies where both a graded treadmill protocol and constant 10 11 grade protocol and below knee and above knee strength were completed and reported, effect 12 sizes and study weighting were averaged, so both outcomes were represented in the meta regression analysis. If inconsistency remained, it was decided that the random effects model 13 14 used accounted for any other differences between studies.

15

16 <u>Reporting Bias</u>

If, as according to Cochrane more than 10 studies were included in an outcome analysis,
funnel plot symmetry was used to detect reporting bias(41). Funnel plots are provided in
supplementary file.

20

21 **Results**

22 Included studies

Overall, 18 studies met the inclusion criteria for this analysis(22, 24-28, 45-56). Fourteen 1 2 studies compared RT to a control group of usual medical care. Seven studies compared RT 3 to an aerobic exercise group(22, 24, 25, 27, 47, 48, 55), 3 of these also had a control group(24, 25, 27). Seventeen studies published or provided enough data to be included in the 4 quantitative analysis, Figure 1. Study quality and risk of bias is outlined in Supplementary 5 6 Table 1. On average, study quality was moderate, with most trials failing to blind outcome 7 assessors in the trials potentially leading to a detection bias, where there could be a difference 8 between groups in how outcomes are determined.

9

10 <u>Participant Characteristics</u>

In total 826 participants were studied, with 363 completing a RT intervention. Mean age was 67.1±3.8 years, range 61 to 74, and on average 68% of participants studied were male. Mean ankle brachial index was 0.66±0.23, range 0.54 to 0.75. Cardiovascular risk factors such as body mass index, waist circumference and blood pressure were poorly reported across studies.

16

17 Intervention Characteristics

18 Characteristics of the RT interventions are outlined in Table 1. Program length varied from 6 19 to 24 weeks, (18±7 weeks). Average training frequency was 3 times per week. Six trials 20 trained participants twice a week(22, 47, 49, 50, 54, 55), one trial four times a week(45) and 21 one trial daily(53). Intensity ranged from light (30% 1RM)(26) to high at 80% 1RM(26, 57) 22 and the number of different exercises performed ranged from 1 to 14 (7±4 exercises), while 23 the number of sets for each type of exercises ranged from 1 to 3, when reported, with the 24 most common number being 3. The number of repetitions per set when reported ranged from

1 6 to 15 (10±5 reps). Exercises involved the use of arms, legs and trunk in six studies(22, 26, 2 28, 48-50), the upper limb only in one study(27) and the lower limb in the remainder of studies(24, 25, 45-47, 51-56). One study focussed only on the calf muscles, using 3 plantarflexion as the chosen exercise(56). Nine trials reported using a circuit training 4 protocol(45, 46, 49-54, 56), while the remaining studies(22, 24-28, 47, 48, 55) had 5 participants complete 1-3 sets of 3 to 14 reps of dynamic exercise, with 2-3 minute rests 6 7 intervals between sets. Duration of exercise sessions ranged from 20 through to 60 minutes. Ten trials(22, 24-28, 47, 48, 53, 55) reported that the RT was progressed weekly during the 8 9 exercise sessions; in the remaining trials progression was not reported. Out of the 18 trials, 8(22, 24-28, 48, 55) reported that RT did not produce claudication pain, 8 trials(26, 46, 47, 10 51-53) reported mild pain and 2 trials(49, 50) reported moderate pain. 11

12

13 The Effect of RT vs. Control/Usual Care Condition

14 <u>Claudication Onset Distance (COD)</u>

In the eight studies(26, 46, 49, 50, 52-54, 56) measuring this outcome RT lead to a significant
improvement in COD on a constant grade treadmill protocol; SMD 0.64 [0.38, 0.90];
P<0.00001, with zero heterogeneity I²=0%; p=0.57, Figure 2a.

In the five studies (24-28, 46) measuring this outcome (across 6 interventions), RT lead to a significant improvement in COD on a progressive grade treadmill protocol; SMD 0.81 [0.09, 1.52]; p=0.03, however, heterogeneity was substantial at $I^2=61\%$; p=0.02, Figure 2b. When only machine-based training studies (free weights excluded) were analysed, heterogeneity was reduced; $I^2=42\%$; p=0.14; however the pooled effect was no longer significant SMD 0.53[-0.07, 1.13]; p=0.08. 1

In the three studies(26-28, 46) that measured it, (across 4 interventions), RT lead to a
clinically meaningful improvement in COD during the 6-minute walk; MD 82.23m [40.91,
123.54]; p<0.0001, with zero heterogeneity I²=0%; p=0.46, Figure 2c.

5

6 <u>Total Walking Distance (WD)</u>

Nine studies completed a constant grade treadmill protocol(26, 45, 46, 49, 50, 52-54, 56)
(across 10 interventions). In the studies that measured it, RT lead to a significant
improvement in WD in this protocol; SMD 0.48 [0.18, 0.78]; p=0.002, with minimal
heterogeneity I²=33%; p=0.14, Figure 3a.

11

Five studies(24-28) used a progressive grade treadmill protocol. In these studies, RT lead to a
significant improvement in total WD; SMD 0.46 [0.09, 0.82]; p=0.01, with zero
heterogeneity I²=0%; p=0.66, Figure 3b.

15

In the four studies that measured 6-minute walk (across five interventions)(25-28) RT did not
significantly improve WD; MD 25.56m [-3.12, 54.24], p=0.08; and there was minimal
heterogeneity across studies I²=34%; p=0.19, Figure 3c.

19

20 <u>The Effect of Resistance Training compared to Walking Training</u>

Five studies(22, 24, 25, 48, 55) compared RT to supervised treadmill walking training. There
were only 2 studies(47, 55) that reported claudication onset during the 6-MWT; therefore,
these data were unable to be combined and analysed. For 6-MWT distance, 4 studies reported
enough data to be included in the analysis. Treadmill walking training was significantly
better than RT, however this difference was not clinically meaningful; MD -16.04m [-27.48, 4.60], p=0.006; I²=0%, p=0.68; Figure 4a.

Five studies reported enough data to analyse progressive treadmill COD. Treadmill walking
training was significantly better than RT; SMD -0.47 [-0.85, -0.08], p=0.02; Figure 4b.
Notably, heterogeneity was moderate and significant at I²=59%, p=0.04. However, when high
intensity studies alone were analysed, the difference between walking distances for treadmill
COD was no longer significant and heterogeneity reduced substantially: progressive treadmill
COD; SMD -0.30 [-0.68, 0.07], p=0.11; I²=13%, p=0.32; Figure 4c.

Five studies reported enough data to analyse progressive treadmill total WD. Treadmill walking training was not significantly better than RT; SMD -0.38 [-0.80, 0.04], p=0.07; Figure 4d). However, heterogeneity was again moderate at $I^2=66\%$, p=0.02. When moderateto-high intensity studies only were analysed, there was still no significant difference between treadmill training and RT, but heterogeneity was eliminated; SMD -0.27 [-0.60, 0.06], p=0.10; $I^2=0\%$, p=0.60; Figure 4e. As there were only 3 studies, this result warrants further exploration.

20

21 Moderator Analysis for Identifying Optimal Exercise Prescriptive Elements

22 The Effect of Intensity of RT

Random effects meta-anova results indicate that higher intensity RT leads to greater
improvements in total WD (B=0.53; p=0.03; low intensity (n=5) mean effect size (ES)=-0.21
[-0.74, 0.29]; moderate intensity (n=6) ES=0.46 [-0.25, 0.67]; and high intensity (n=2)
ES=0.66 [0.24, 1.07]; with between group p=0.02).

5

6 The Effect of Muscle Groups Trained

Random effects meta-anova results indicate that lower body RT leads to a greater
improvement in total WD (lower body mean ES=0.67; whole body mean ES=0.39. However,
the between group difference was not significant p=0.09).

10

No statistically significant relationships with any other prescriptive elements or participant
characteristics were identified.

13

14 <u>Muscle Strength Testing</u>

Although ten studies(24-28, 47, 48, 55, 57) reported muscle strength as an outcome, only four(24-26, 28) reported enough information to be included in the analysis. All four studies used a version of repetition maximum (RM) testing. Two studies(25, 26) completed a 1RM with no adverse events, one study(24) completed a 5RM on the calf muscles only and the last study completed a 10RM. Overall RT improved muscle strength with a small ES; SMD 0.43 [0.16, 0.70]; p=0.002, with zero heterogeneity; I²=0%, p=0.65; Figure 5. Strength improved more robustly in the upper leg/above knee muscles of the claudicants, where a moderate ES was noted; SMD 0.71 [0.29, 1.13], p=0.0009; and results were similar across trials; I²=0%,
p=0.70.

3

4 <u>Risk of Publication Bias</u>

5 The number of trials reaching 10 only occurred in two outcomes; constant grade treadmill 6 total WD and change in overall muscle strength. Funnel plots for each of the analyses are 7 presented in Figure 1 and Figure 2 of the Supplementary material. Funnel plots are 8 symmetrical and do not indicate publication bias for either outcome.

9

10 **Discussion**

Patients with PAD have reduced leg strength and function(22, 26). This study has shown that RT improves leg strength and both flat ground and graded walking distances in persons with PAD. Furthermore, supervised RT programs can also improve each of the individual risk factors for cardiovascular disease in older healthy adults(58), Trials of RT in persons with PAD therefore warrant further research to identify whether different prescriptions (i.e. adjusting frequency and intensity) may be more effective in individual patients with PAD with varied cardiovascular risk profiles.

18

19 Effects of RT on walking capacity

This analysis has shown that RT alone improves walking ability for persons with PAD. The mechanisms underlying these effects have been explored in few studies. RT increases muscle mass(28) and muscle strength(22, 26), measures that are already reduced in patients with PAD(21). This meta-analysis included studies showing a strong association between the

changes in strength levels and the changes in walking capacity after RT(22, 26), suggesting
 that strength gains leads to lowers muscle fibre recruitment during walking, thereby reducing
 the energy cost of walking. However, as only 4 studies included in this analysis reported
 strength testing results, it was difficult to explore this relationship.

5

6 Walking exercise has been recommended as the primary mode of exercise for patients with 7 PAD. Therefore, the comparison of walking exercise against RT is useful to understand the 8 effects of RT compared to this gold-standard mode of exercise for PAD patients. This meta-9 analysis indicated superior effects of walking exercises compared to RT. However, when subgroup analyses were conducted, high intensity RT produced similar increases in walking 10 capacity assessed during a maximal graded treadmill test compared to walking training. 11 12 Although we could not compare the effects of RT against walking training during the 6-MWT because there were too few studies, the similar effects of high intensity RT compared 13 14 to walking training assessed during graded treadmill tests, suggest that high intensity RT may 15 be a feasible alternative therapy to walking for patients with PAD. This could help improve adherence of exercise programs, given that patients have reported RT as being less painful 16 17 than walking training(22).

18

Elements of the most effective RT interventions and recommendations for future research
When we examined which elements of interventions were associated with large, significant
improvements in walking ability, high intensity RT of the lower body was the most effective
element. Exercises focussing on the lower body: calf muscles, quadriceps, hamstrings and
gluteals were included in the interventions with the larger effects. Further comparisons of RT
intensity would be better verified with direct comparisons [i.e. moderate 60% 1RM versus
high intensity (80% 1RM] within trials. Only one study has done this to date(26), results of

which showed the ineffectiveness of low intensity (30% 1RM) training against the efficacy of
high intensity (80% 1RM). Other elements of exercise prescription such as frequency of
training sessions, length of program, and whether whole body exercises are more beneficial
than lower limb only, remain unclear and need to be tested explicitly.

5

6 <u>Limitations</u>

7 Though poorly reported, some studies showed that the changes in walking distance were 8 associated with changes in above knee leg strength(22, 26). The lack of strength testing of 9 participants and/or lack of reporting testing results in the included trials is a major limitation of this literature. Future trials should ensure baseline strength measures are completed prior 10 to commencement of strength training in order to ensure appropriate overload and 11 12 progression is consistently applied to the training muscles. Furthermore, trials should report both the baseline and follow up strength test results for individual muscle groups, along with 13 14 changes in walking distances so the relationship between leg strength and walking distance can be explored further in future meta-analyses. 15

16

As cardiovascular risk is increased in this cohort, future trials should also report the effect of 17 18 the exercise training on cardiovascular risk factors such as body mass index, waist circumference, arterial stiffness, inflammation, and blood pressure. Research should also 19 include more women and culturally and linguistically diverse cohorts. Outcomes should 20 21 including measures of quality of life and physical function such as balance, chair stand, gait speed and stair climb power, in order to identify RT prescriptions that are most efficacious at 22 improving performance of activities of daily living. Finally, studies need to report and 23 investigate more prescriptive elements of strength training including the number of exercises, 24

1 intensity and frequency of exercise training, and conduct longer follow up testing in an effort

2 to identify how long the effects of RT are maintained.

3

4 **Disclosures**

5 The authors disclose no conflicts of interest for this research.

6

7 License

8 * I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive 9 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has 10 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for 11 US Federal Government officers or employees acting as part of their official duties; on a 12 13 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the 14 15 Journal, to publish the Work in British Journal of Sports Medicine and any other BMJ products and to exploit all rights, as set out in our licence. 16 17 The Submitting Author accepts and understands that any supply made under these terms is 18 19 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of

20 your employer or a postgraduate student of an affiliated institution which is paying any

- applicable article publishing charge ("APC") for Open Access articles. Where the Submitting
- 22 Author wishes to make the Work available on an Open Access basis (and intends to pay the
- relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
- 24 Commons licence details of these licences and which <u>Creative Commons</u> licence will apply
- 25 to this Work are set out in our licence referred to above.
- 26
- 27
- 28

1 References

2 1. Benjamin E, Blaha M, Chiuve S, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association Circulation. 2017. 3 2. Gerhard-Herman M, Gornik H, Barrett C, et al. AHA/ACC Guideline on the 4 5 Management of Patients With Lower Extremity Peripheral Artery Disease. Circulation. 6 2016;135(12):e726-e79. McDermott M, Guralnik J, Albay M, et al. Impairments of muscles and nerves 7 3. associated with peripheral arterial disease and their relationship with lower extremity 8 9 functioning: the InCHIANTI Study. J Am Ger Soc. 2004;52(3):405-10. Parmenter B, Raymond J, Dinnen P, et al. Preliminary evidence that low ankle 10 4. brachial index is associated with reduced bilateral hip extensor strength and functional 11 mobility in peripheral arterial disease. J Vasc Surg. 2013;57(4):963-73. 12 McDermott M, Criqui M, Greenland P, et al. Leg strength in peripheral arterial 13 5. disease: associations with disease severity and lower-extremity performance. J Vasc Surg. 14 2004;39(3):523-30. 15 Garg P, Liu K, Ferrucci L, et al. Lower extremity nerve function, calf skeletal muscle 16 6. characteristics, and functional performance in peripheral arterial disease. J Amer Ger Soc. 17 18 2011;59:1855-63. 7. King S, Vanicek N, O'Brien T. Dynamic muscle quality of the plantar flexors is 19 impaired in claudicant patients with peripheral arterial disease and associated with poorer 20 walking endurance. J Vasc Surg. 2015;62(3):689-97. 21 Myers S, Johanning J, Stergiou N, et al. Gait variability is altered in patients with 22 8. peripheral arterial disease. J Vasc Surg. 2009;49(4):924-31 e1. 23 24 9. King S, Vanicek N, O'Brien T. Sagittal plane joint kinetics during stair ascent in 25 patients with peripheral arterial disease and intermittent claudication. Gait & Posture. 2017:55:81-6. 26 27 10. King S, Vanicek N, O'Brien T. Joint moment strategies during stair descent in patients 28 with peripheral arterial disease and intermittent claudication. Gait Posture. 2018;62:359-65. 29 11. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte M, 30 Pomposelli F, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and 31 claudication. J Vasc Surg. 2015;61(3 Supplement):2S-41S. 32 33 12. Anderson J, Halperin J, Albert N, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of 34 the American College of Cardiology Foundation/American Heart Association Task Force on 35 Practice Guidelines. Circulation. 2013;127(13):1425-43. 36 13. Dörenkamp S, Mesters I, de Bie R, et al. Patient Characteristics and Comorbidities 37 Influence Walking Distances in Symptomatic Peripheral Arterial Disease: A Large One-Year 38 Physiotherapy Cohort Study. PLoS One. 2016;11(1):e0146828. 39 Cunningham M, Swanson V, Holdsworth R. Using a psychological model to 40 14. investigate the relationship between illness beliefs and walking behaviour ofpatients with 41 intermittent claudication. Br J Surg. 2010;97(Supp 1):6. 42 43 15. Katzel L, Sorkin J, Powell C, et al. Comorbidities and exercise capacity in older patients with intermittent claudication. Vasc Med. 2001;6(3):157-62. 44 Barbosa J, Farah B, Chehuen M, et al. Barriers to physical activity in patients with 45 16. 46 intermittent claudication. Int J Behav Med. 2015;22(1):70-5. 47 17. Garg P, Tian L, Criqui M, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation. 2006;114:242-8. 48

18. Oka R, Szuba A, Giacomini J, et al. Predictors of physical function in patients with 1 peripherial arterial disease and claudication. Prog Cardiovasc Nurs. 2004;19(3):89-94. 2 Parmenter B, Raymond J, Dinnen P, et al. Preliminary evidence that low ankle-3 19. brachial index is associated with reduced bilateral hip extensor strength and functional 4 mobility in peripheral arterial disease. J Vasc Surg. 2013;57(4):963-73. 5 Parmenter B, Dieberg G, Smart N. Exercise training for management of peripheral 6 20. 7 arterial disease: a systematic review and meta-analysis. Sports Med. 2015;45(2):231-44. McDermott M, Liu K, Tian L, et al. Calf muscle characteristics, strength measures, 8 21. and mortality in peripheral arterial disease: a longitudinal study. J Am Coll Cardiol. 9 2012;59(13):1159-67. 10 Ritti-Dias R, Wolosker N, Forjaz C, et al. Strength training increases walking 11 22. tolerance in intermittent claudication patients: Randomized trial. J Vasc Surg. 2010;51(1):89-12 13 95. Parmenter B, Dieberg G, Phipps G, et al. Exercise training for health-related quality 23. 14 of life in peripheral artery disease: A systematic review and meta-analysis. Vasc Med. 15 2015;20(1):30-40. 16 17 24. Hiatt W, Wolfel E, Meier R, et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism 18 of the training response. Circulation. 1994;90(4):1866. 19 20 25. McDermott M, Ades P, Guralnik J, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: A 21 randomized controlled trial. JAMA - Journal of the American Medical Association. 22 23 2009;301(2):165-74. Parmenter B, Raymond J, Dinnen P, et al. High-intensity progressive resistance 24 26. training improves flat-ground walking in older adults with symptomatic peripheral arterial 25 26 disease. Journal of the American Geriatrics Society. 2013;61(11):1964-70. Parr B, Noakes T, Derman E. Peripheral arterial disease and intermittent claudication: 27 27. Efficacy of short-term upper body strength training, dynamic exercise training, and advice to 28 exercise at home. South African Medical Journal. 2009;99(11):800-4. 29 McGuigan M, Bronks R, Newton R, et al. Resistance training in patients with 30 28. peripheral arterial disease: effects on myosin isoforms, fiber type distribution, and capillary 31 supply to skeletal muscle. J Gerontol A Biol Sci Med Sci. 2001;56(7):B302-10. 32 29. Halbert J, Silagy C, Finucane P, et al. Exercise training and blood lipids in 33 hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. 34 European journal of clinical nutrition. 1999;53(7):514-22. 35 36 30. Hordern MD, Dunstan DW, Prins JB, et al. Exercise prescription for patients with type 2 diabetes and pre-diabetes: A position statement from Exercise and Sport Science 37 Australia. Journal of Science and Medicine in Sport. 2012;15(1):25-31. 38 39 31. MacDonald H, Johnson B, Huedo-Medina T, et al. Dynamic Resistance Training as Stand-Alone Antihypertensive Lifestyle Therapy: A Meta-Analysis. Journal of the American 40 Heart Association. 2016;5(10). 41 42 32. Whelton S, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a metaanalysis of randomized, controlled trials. Annals of internal medicine. 2002;136(7):493-503. 43 Yang Z, Scott C, Mao C, et al. Resistance exercise versus aerobic exercise for type 2 33. 44 45 diabetes: a systematic review and meta-analysis. Sports Med. 2014;44(4):487-99. Gomes APF CM, Soares AHG, Cucato GG, Lima AHRA, Cavalcante BR, Sobral-34. 46 Filho DC, Ritti-Dias RM. Effects of Resistance Training on Cardiovascular Function in 47 48 Patients With Peripheral Artery Disease: A Randomized Controlled Trial. J Strength Cond Res. 2018;32(4):1072-80. 49

strength training on resting and exercise cardiovascular responses in patients with intermittent 2 claudication. VASA. 2011;40(5):390-7. 3 36. Askew C, Parmenter B, Leicht A, et al. Exercise & Sports Science Australia (ESSA) 4 position statement on exercise prescription for patients with peripheral arterial disease and 5 intermittent claudication. J Sc Med Spp. 2014;17:623-29. 6 7 37. American College of Sports Medicine AS, Baruith M, Baynard T, Beck D and et al. ACSM Guidelines for Exercise Testing and Prescription. . Tenth ed. Philadelphia PWKH, 8 9 editor2018. 38. Garber C, Blissmer B, Deschenes M, et al. Quantity and quality of exercise for 10 developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in 11 apparently healthy adults: Guidance for prescribing exercise. Med Sci Sp Ex. 2011;43:1334-12 13 59. 39. American College of Sports Medicine, Agiovlasitis S, Baruith M, et al. ACSM 14 Guidelines for Exercise Testing and Prescription. Tenth ed. Riebe D, editor. Philadelphia, 15 PA.: Wolters Kluwer Health; 2018. 16 17 40. Borg G. Perceived exertion: a note on "history" and methods. . Med Sci Sports. 1973;5:90-3. 18 Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 19 41. 20 West Sussex, England.: John Wiley & Sons Ltd; 2008. 42. Drahota A, Beller E. Cochrane RevMan Calculator [Available from: 21 22 https://training.cochrane.org/resource/revman-calculator. 23 43. Rasekaba T, Lee A, Naughton M, et al. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009;39(8):495-501. 24 Wilson D. Meta-analysis macros for SAS, SPSS and Stata. 2005 [Available from: 25 44. 26 http://mason.gmu.edu/ dwilsonb/ma. Cheetham D, Burgess L, Ellis M, et al. Does supervised exercise offer adjuvant 27 45. benefit over exercise advice alone for the treatment of intermittent claudication? A 28 randomised trial. Eur J Vasc Endovasc Surg. 2004;27:17-23. 29 Dahllöf AG, Björntorp P, Holm J, et al. Metabolic Activity of Skeletal Muscle in 46. 30 Patients with Peripheral Arterial Insufficiency: Effect of Physical Training. European Journal 31 of Clinical Investigation. 1974;4(1):9-15. 32 47. Delaney C, Miller M, Chataway T, et al. A randomised controlled trial of supervised 33 exercise regimens and their impact on walking performance, skeletal muscle mass and 34 Calpain activity in patients with intermittent claudication. European Journal of Vascular and 35 36 Endovascular Surgery. 2014;47(3):304-10. 37 Gardner A, Parker D, Montgomery P, et al. Step-monitored home exercise improves 48. ambulation, vascular function, and inflammation in symptomatic patients with peripheral 38 39 artery disease: A randomized controlled trial. Journal of the American Heart Association. 40 2014;3(5). 49. Hobbs S, Marshall T, Fegan C, et al. The constitutive procoagulant and 41 42 hypofibrinolytic state in patients with intermittent claudication due to infrainguinal disease significantly improves with percutaneous transluminal balloon angioplasty. J Vasc Surg. 43 44 2006;43:40-6. 45 50. Hobbs S, Marshall T, Fegan C, et al. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial. J 46 Vasc Surg. 2007;45:65-70. 47 48 51. Holm J, Dahllof AG, Bjorntorp P, et al. Enzyme studies in muscles of patients with intermittent claudication. Effect of training. Scandinavian Journal of Clinical and Laboratory 49 Investigation. 1973;31(SUP.128):201-5. 50

Grizzo Cucato G, de Moraes Forjaz C, Kanegusuku H, et al. Effects of walking and

35.

- 52. Lundgren F, Dahloff A, Lundholm K, et al. Intermittent Claudication: Surgical
 Reconstruction or Physical Training. Ann Surg. 1989;209(3):346-55.
- 3 53. Mannarino E, Pasqualini L, Innocente S, et al. Physical Training and Antiplatelet
- 4 Treatment in Stage II Peripheral Arterial Occlusive Disease: Alone or Combined? .
- 5 Angiology. 1991;42(7):513-21.
- 6 54. Stewart A, Smith F, Baird R, et al. Local versus systemic mechanisms underlying
- supervised exercise training for intermittent claudication. Vasc Endovasc Surg.
 2008;42(4):314-20.
- 9 55. Szymczak M, Oszkinis G, Majchrzycki M. The Impact of Walking Exercises and
- 10 Resistance Training upon the Walking Distance in Patients with Chronic Lower Limb
- 11 Ischaemia. Biomed Research International. 2016:8.
- 56. Tebbutt N, Robinson L, Todhunter J, et al. A plantar flexion device exercise
 programme for patients with peripheral arterial disease: A randomised prospective feasibility
 study. Physiotherapy. 2011;97(3):244-9.
- 15 57. Albaghdadi M, Wang Z, Gao Y, et al. High-Density Lipoprotein Subfractions and
- 16 Cholesterol Efflux Capacity Are Not Affected by Supervised Exercise but Are Associated
- with Baseline Interleukin-6 in Patients with Peripheral Artery Disease. Front CardiovascMed. 2017;4:10.
- 19 58. Ratamess N, Alvar B, Evetoch T, et al. Progression Models in Resistance Training for
- Healthy Adults: ACSM Position Stand. Med Sci Sp Ex. 2009;41(3):687-708.
- 21

22

23

24

25

26

27

28

29

30

31

32

33

34

1 Figure Legend

2 Figure 1: PRISMA Flow chart for study identification. N= number; RT= Resistance training; 3 RCT= Randomised controlled trial; PAD= Peripheral artery disease. 4 Figure 2: Claudication Onset Distance for (A) Constant grade treadmill protocol; (B) 5 Progressive grade treadmill protocol; and (C) 6-minute walk. SD= Standard deviation, CI= Confidence interval, RT= Resistance training, INR= Intensity not reported, Mod=Moderate. 6 7 Figure 3: Total Walking Distance for (A) Constant grade treadmill protocol; (B) Progressive grade treadmill protocol; and (C) 6-minute walk. SD= Standard deviation, CI= Confidence 8 9 interval, RT= Resistance training, INR= Intensity not reported, Mod=Moderate. 10 Figure 4: (A) 6-MWT distance for RT vs Trd training trials; (B) Progressive treadmill COD RT vs Trd training; (C) Progressive treadmill COD Mod-High Intensity RT vs Trd training; 11 (D) Progressive treadmill total WD RT vs Trd training; (E) Progressive treadmill total WD 12 Mod-High Intensity RT vs Trd training. SD= Standard deviation, CI= Confidence interval, 13 RT= Resistance training, Mod=Moderate, RT= Resistance training; Trd= Treadmill; COD= 14 15 Claudication onset distance; WD= Walking distance. Figure 5: Change in muscle strength across studies measuring 2.1.1 Below knee muscle 16 strength; 2.1.2 Above knee muscle strength; and 2.1.3 Whole body muscle strength. SD= 17 Standard deviation, CI= Confidence interval, RT= Resistance training, INR= Intensity not 18 19 reported, Mod=Moderate.

- 20
- 21
- 22
- 23

								Strengtl	h Training In	terven	tion Ch	aracterist	tics	
Author	Group	Sample	Sex	Age	ABI	RT method	Freq	Session	Intensity*	N of	Area	N of	N of	Prog
	(n)	size	(%	(yrs)		and Type of	(per	length		ex	of ex	sets or	reps/set	length
		(n)	male)			Resistance	week)	(mins)				ex:rest		(wks)
												ratio		
Strength train	ing versu	is usual ca	re contro	1										
Cheetham	ST	29	73	67	0.69	Dynamic	4	28	Self-paced	7	LB	2:2	mins	24
2004	Con	30				Circuit BW								
Dahloff	ST	10	72	61	NR	Dynamic	3	30	NR	NR	LB	NR	NR	24
1974	Con	8				Circuit BW								
Hobbs 2006	ST	7	71	72	0.70	Dynamic	2	60	Mod	11	WB	3:2	mins	12
	Con	7				circuit BW								
Hobbs 2007	ST	9	72	67	0.75	Dynamic	2	60	Mod	11	WB	3:2	mins	12
	Con	9		_		circuit BW								
Holm 1973	ST	6	NR	63	NR	Dynamic	3	30	NR	NR	LB	NR	NR	24
	Con	6				circuit BW								
Lundgren	ST	25	NR	64	0.57	Dynamic	3	30	NR	NR	LB	NR	NR	24
1989	Con	25			0.67	circuit BW	_			-				
Mannarino	ST	10	67	63	0.67	Dynamic	7	60	NR	6	LB	NR	NR	24
1991	Con	10	70	60	0.67	circuit BW	2	10		~	I D	ND	ND	10
Stewart	ST	30	/0	68	0.67	Dynamic	2	40	NR	5	LB	NR	NR	12
2008	Con	30		60	0.00	circuit BW	1	20	T • 1.	1	C 16	2.2		10
Tebbut	ST	18	6/	69	0.69	Dynamic	1	20	Light-	1	Calf	2:2	mins	12
2010	Con	24				Plantar-			mod					
II:	ст	0	100	(7	0.50	Demonstra	2	ND	N (- 1	5	τD	2	(10
Hiatt 1994	SI Corr	9	100	67	0.56	Dynamic	3	NK	Mod	5	LB	3	0	12
MaDanmast	CON	10	10	70	0.61	ΓW	2	ND	Mad	5	тD	2	0	24
and	SI Con	52 40	4ð	/0	0.01	Dynamic M	3	INK	NIOU	3	LD	3	ð	24
2009	Con	40												

Table 1 Intervention Characteristics

McGuigan	ST Con	11 o	46	70	0.64	Dynamic M/FW/BW	3	NR	Mod-High	8	WB	3	8	24
Parmenter	ST 1 ST 2	7 7 7	64	73	0.54	Dynamic M	3	60	Light High	7	WB	3	8	24
2013	Con	7				Dynamic W			Ingn					
Parr 2009	ST	9	68	62	NR	Dynamic	3	NR	Mod	14	UB	1	15	6
	Con	8				M/FW								
Strength train	ing versu	is other exer	cise											
Delaney	ST	17	77	69	0.72	Dynamic M	2	60	Light	6	LB	3	8 to 12	12
2014	Alt Ex	18	67	73	0.71	Trd walk	2	60	Self-paced			Max	pain:rest	12
Gordnor	ST	60	60	65	0.74	Dynamic M		NR	Light	9	WB	1	15	
2014	Alt Ex	60	52	67	0.68	Home walk	3	20 ↑ - 45	Self-paced			Mild Ma	d nain-rast	12
2014	Alt Ex	60	48	65	0.68	Trd walk		15 ↑ - 40	40% peak			wing-wie	ju pam.iest	
Ujott 100/	ST	See above												
111att 1994	Alt Ex	10	100	67	0.55	Trd walk	3	60	Self-paced			Mod	pain:rest	12
McDermott	ST	See above												
2009	Alt Ex	51	47	72	0.60	Trd walk	3	15 ↑ - 40	Mod			Mod-ma	x pain:rest	24
Ritti-Dias	ST	15	60	66	0.63	Dynamic M	2	60	Mod	8	WB	3	10	12
2010	Alt Ex	15	73	65	0.66	Trd walk	2	00	widd			2:2 mins	s mild pain	12
Szymczak	ST	26	ND	ND	0.67	Dynamic M	2	50	Light-mod	6	LB	3	15	12
2016	Alt Ex	24	INK	INK	0.07	Trd walk	2	50	Self-paced			Mil	d pain	12

N= number; ST= strength training; Ex= exercise; Freq= frequency; Mins= minutes; Con= control; RT= resistance training; RM=

repetition maximum; LB= lower body; UB= upper body; WB= whole body; BW= body weight; M= machine based training; FW=

free weights; NR= not reported; Mod= moderate; Vig= vigorous; Alt Ex= Alternate exercise; Vol*= volume (sets x repetitions x

days); Prog= progression;

* According to American College of Sports Medicine;



	Resista	ince Trai	ning	0	Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
A. Constant grade	treadmill	protocol							
Tebbutt (RT Light-Mod)	20	81	24	0	119.2	18	18.1%	0.20 [-0.41, 0.81]	
Parmenter (RT Light)	139.6	299.3	7	77.8	86.3	3	3.7%	0.21 [-1.15, 1.57]	
Hobbs (RT Mod 06)	33	22	9	9	70	9	7.7%	0.44 [-0.50, 1.38]	
Lundgren (RT INR)	489	380	25	320	351	25	21.5%	0.45 [-0.11, 1.02]	
Parmenter (RT High)	117.2	71.9	7	77.8	86.3	4	4.3%	0.47 [-0.78, 1.72]	
Stewart (RT INR)	49.4	40	30	15.8	34	30	24.0%	0.89 [0.36, 1.43]	│ — -
Hobbs (RT Mod 07)	50	40	9	14	19.2	9	6.7%	1.09 [0.08, 2.10]	-
Dahloff (RT INR)	174	150.3	10	0.01	152.6	8	6.6%	1.10 [0.08, 2.11]	-
Mannarino (RT INR)	107.2	63	10	36.3	49.4	10	7.2%	1.20 [0.23, 2.17]	
Subtotal (95% CI)			131			116	100.0%	0.64 [0.38, 0.90]	•
Heterogeneity: Tau ² = 0.0	0; Chi ² = 6	6.74, df=	8 (P = 0	.57); l² =	= 0%				
Test for overall effect: Z =	4.83 (P <	0.00001)							

Parmenter (RT Light)	62.6	117.3	7	65.2	68.8	3	14.3%	-0.02 [-1.37, 1.33]	
McDermott (RT Mod)	86.6	166.9	46	70.2	177.9	20	25.4%	0.10 [-0.43, 0.62]	_ _
Parr (RT Mod)	157	358	9	13.7	67	4	16.2%	0.43 [-0.76, 1.63]	
McGuigan (RT Mod-High)	153.6	228.6	11	-8.3	10.7	9	19.6%	0.91 [-0.03, 1.84]	
Parmenter (RT High)	229.1	72.3	7	65.2	68.8	4	11.5%	2.11 [0.46, 3.75]	_
Hiatt (RT Mod) Subtotal (95% CI)	16	20.7	9 89	-37.4	23.7	5 45	13.0% 100.0%	2.30 [0.81, 3.78] 0.81 [0.09, 1.52]	•
Heterogeneity: Tau ² = 0.45;	Chi ² = 12	.89, df = 5	(P = 0.0	02); I ² =	61%				_
Test for overall effect: Z = 2.3	22 (P = 0.)	03)							

	Resista	ance Trai	ning	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
C. Six minute walk									
Parmenter (RT Light)	-2.9	262.4	7	-44.6	38.3	3	4.3%	41.70 [-157.46, 240.86]	
Parr (RT Mod)	27	71	9	-30	29	4	57.7%	57.00 [2.60, 111.40]	→
Parmenter (RT High)	77.3	93.1	7	-44.6	59.7	4	20.9%	121.90 [31.46, 212.34]	_
McGuigan (RT Mod-High)	113	167.3	11	-16	20.9	9	17.1%	129.00 [29.20, 228.80]	
Subtotal (95% CI)			34			20	100.0%	82.23 [40.91, 123.54]	-
Heterogeneity: Tau ² = 0.00; (Chi² = 2.5	7, df = 3 i	(P = 0.4)	6); I ² = 0	1%				
Test for overall effect: Z = 3.9	30 (P < 0.1	0001)							
									Favours control Favours RT

-2 -1 0 1 Favours control Favours RT

2

A. Constant grade	readmill	protocol							
Parmenter (RT Light)	152.7	412.8	7	677.3	872.1	3	3.9%	-0.84 [-2.27, 0.59]	
Hobbs (RT Mod 06)	13	134	9	61	118	9	7.9%	-0.36 [-1.30, 0.57]	
Parmenter (RT High)	830.4	1,411.2	7	677.3	872.1	4	5.1%	0.11 [-1.12, 1.34]	
Lundgren (RT INR)	474	380	25	361	335	25	15.4%	0.31 [-0.25, 0.87]	- +-
Tebbutt (RT Light-Mod)	40	203.5	24	-50	282.8	18	13.8%	0.37 [-0.25, 0.98]	- +-
Cheetham (RT INR)	170	243.8	28	71	101.8	28	16.1%	0.52 [-0.01, 1.06]	
Stewart (RT INR)	92.4	145	30	16.1	47	30	16.4%	0.70 [0.18, 1.22]	— -
Hobbs (RT Mod 07)	119	128	9	43	66.4	9	7.6%	0.71 [-0.25, 1.67]	
Dahloff (RT INR)	362	205	10	0.01	324.5	8	6.6%	1.31 [0.26, 2.35]	—
Mannarino (RT INR) Subtotal (95% CI)	168.6	81.3	10 159	56.9	76.5	10 144	7.2% 100.0%	1.36 [0.36, 2.35] 0.48 [0.18, 0.78]	→
Heterogeneity: $Tau^2 = 0.0$	7: Chi ² =	13.49. df=	9 (P = (0.14): I ^z	= 33%				

-2 -1 0 1 2 Favours control Favours RT

Parmenter (RT Light)	10.6	137	7	47.9	171	3	7.4%	-0.23 [-1.59, 1.13]	
Parr (RT Mod)	7	19.8	8	7.3	46	4	9.5%	-0.01 [-1.21, 1.19]	
Parmenter (RT High)	73.5	132.3	7	47.9	171	4	9.0%	0.16 [-1.07, 1.39]	
McDermott (RT Mod)	124.3	197.4	46	35.5	144.5	20	48.4%	0.48 [-0.05, 1.01]	↓ − ∎ −−
McGuigan (RT Mod-High)	186.8	269	11	0.01	0.01	9	15.7%	0.89 [-0.04, 1.83]	
Hiatt (RT Mod)	106.8	138.2	9	-5.3	3.4	5	10.0%	0.93 [-0.24, 2.10]	
Subtotal (95% CI)			88			45	100.0%	0.46 [0.09, 0.83]	◆
Heterogeneity: Tau ² = 0.00;	Chi ² = 3.2	6, df = 5 ((P = 0.68	6); i² = 0	1%				
Test for overall effect: Z = 2.	45 (P = 0.1	01)							

	Resista	ance Trai	ning	С	ontrol			Mean Difference		Mean [ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Rand	om, 95% Cl	
C. Six minute walk												
Parr (RT Mod)	13	21	9	2	33	4	32.6%	11.00 [-24.13, 46.13]		-	-	
McDermott (RT Mod)	-2	37.9	46	-15	38.7	20	48.5%	13.00 [-7.19, 33.19]			-	
Parmenter (RT Light)	8.8	192.2	7	-9.9	38.6	3	3.5%	18.70 [-130.23, 167.63]			+•	
Parmenter (RT High)	59.9	166.3	7	-9.9	60.3	4	4.1%	69.80 [-66.83, 206.43]				
McGuigan (RT Mod-High)	85	127.2	11	-23	30.1	9	11.2%	108.00 [30.30, 185.70]				_
Subtotal (95% CI)			80			40	100.0%	25.56 [-3.12, 54.24]			◆	
Heterogeneity: Tau ² = 335.1	8; Chi ² =	6.09, df=	4 (P = 0	0.19); I ² ÷	= 34%							
Test for overall effect: Z = 1.3	75 (P = 0.	08)										
									+		+ +	

-200 -100 0 100 200 Favours control Favours RT

	Resista	nce Tra	ining	Treadr	nill Trai	ning		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
A. 6MWT RT versu	us Trd								
McDermott (Trd Walk)	-2	37.9	46	21	48.6	50	43.4%	-23.00 [-40.36, -5.64]	
Szymczak (Trd Walk)	27.1	71.4	26	41.8	78.1	24	7.6%	-14.70 [-56.29, 26.89]	
Gardner (Trd Walk)	4	40	60	15	52	60	47.5%	-11.00 [-27.60, 5.60]	
Delaney (Trd Walk) Subtotal (95% Cl)	51	165	13 145	32	47	14 148	1.5% 100.0%	19.00 [-74.01, 112.01] - 16.04 [-27.48, -4.60]	•
Heterogeneity: Tau² = 0. Test for overall effect: Z	.00; Chi² = = 2.75 (P =	1.52, df : 0.006)	= 3 (P =	0.68); I² =	= 0%				
									Fougure treadmill Fougure DT

Favours treadmill Favours RT

	Resista	ance Trai	ining	Tread	mill Trai	ning		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
B. Progressive tre	eadmill CC	DD RT ve	rsus Tro						
Gardner (Trd Walk)	15	121.4	60	149.6	160.2	60	26.6%	-0.94 [-1.32, -0.56]	_ -
Hiatt (Trd Walk)	16	20.7	9	181.6	252.4	10	11.2%	-0.86 [-1.81, 0.09]	
McDermott (Trd Walk)	86.6	166.9	46	156.8	261.8	50	25.7%	-0.31 [-0.72, 0.09]	
Szymczak (Trd Walk)	61.7	134.7	26	90.2	64.1	24	20.4%	-0.26 [-0.82, 0.29]	
Ritti-Dias (Trd Walk)	146	224	15	127	182	15	16.0%	0.09 [-0.63, 0.81]	
Subtotal (95% CI)			156			159	100.0%	-0.47 [-0.85, -0.08]	◆
Heterogeneity: Tau ² = 0.	.11; Chi ² =	9.87, df	= 4 (P =	0.04); l²:	= 59%				
Test for overall effect: Z:	= 2.38 (P =	= 0.02)							
									Favours treadmill Favours RT

	Resista	ance Trai	ning	Tread	mill Trai	ning	:	Std. Mean Difference		Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI	
C. Progressive Tro	l COD mo	d-high R	T versu	s Trd							
Hiatt (Trd Walk)	16	20.7	9	181.6	252.4	10	14.4%	-0.86 [-1.81, 0.09]	_		
McDermott (Trd Walk)	86.6	166.8	46	156.8	261.8	50	61.4%	-0.31 [-0.72, 0.09]			
Ritti-Dias (Trd Walk)	146	339.5	15	127	285.4	15	24.2%	0.06 [-0.66, 0.77]			
Subtotal (95% CI)			70			75	100.0%	-0.30 [-0.68, 0.07]			
Heterogeneity: Tau ² = 0.1	02; Chi ^z =	2.30, df=	= 2 (P =	0.32); l²	= 13%						
Test for overall effect: Z =	= 1.59 (P =	= 0.11)									
									⊢		_
									-2	-1 U I	

	Resistance Training		Treadmill Training				Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
D. Progressive Tr	d WD RT v	versus Ti	rd						
Gardner (Trd Walk)	19.4	139.9	60	168	167.2	60	25.5%	-0.96 [-1.34, -0.58]	
Hiatt (Trd Walk)	106.8	138.2	9	272.3	378.6	10	12.6%	-0.54 [-1.46, 0.38]	
McDermott (Trd Walk)	124.3	197.5	46	218.1	364	50	24.8%	-0.31 [-0.72, 0.09]	
Szymczak (Trd Walk)	148.4	223.3	26	146	137.8	24	20.6%	0.01 [-0.54, 0.57]	
Ritti-Dias (Trd Walk)	157	282	15	149	231	15	16.6%	0.03 [-0.69, 0.75]	
Subtotal (95% CI)			156			159	100.0%	-0.38 [-0.80, 0.04]	◆
Heterogeneity: Tau ² = 0.	.14; Chi ² =	11.76, d	f= 4 (P =	= 0.02); I	²= 66%				
Test for overall effect: Z	= 1.79 (P =	= 0.07)							
								-	-2 -1 0 1 2
									Favours treadmill Favours RT

	Resis	stance Train	raining Treadmill Training					Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
E. Progressive Trd WD mod-high RT versus Trd											
Hiatt (Trd Walk)	106.8	138.2	9	272.3	378.6	10	12.7%	-0.54 [-1.46, 0.38]			
McDermott (Trd Walk)	124.3	197.5	46	218.1	364	50	66.3%	-0.31 [-0.72, 0.09]			
Ritti-Dias (Trd Walk)	157	417.4751	15	149	353.3523	15	21.0%	0.02 [-0.70, 0.74]			
Subtotal (95% CI)			70			75	100.0%	-0.27 [-0.60, 0.06]	•		
Heterogeneity: Tau ² = 0.00; Chi ² = 1.01, df = 2 (P = 0.60); i ² = 0%											
Test for overall effect: Z	= 1.63 (P	= 0.10)									
								-			
									Favours treadmill Favours RT		

	Resistance Training		C	ontrol			Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
A. Below Knee										
Parmenter (RT Light)	0	11.5	7	8	6.5	3	3.7%	-0.69 [-2.10, 0.72]		
Hiatt (RT Mod)	4.3	11.6	9	2.7	12.1	5	6.1%	0.13 [-0.97, 1.22]		
McDermott (RT Mod)	117	212.6	46	78.2	194	20	26.5%	0.19 [-0.34, 0.71]		
Parmenter (RT High)	12	19	7	8	6.5	4	4.8%	0.23 [-1.01, 1.46]		
McGuigan (RT Mod-High)	55	81.4	11	6.6	8.6	9	8.7%	0.76 [-0.16, 1.68]		
Subtotal (95% CI)			80			41	49.7%	0.22 [-0.17, 0.60]	★	
Heterogeneity: Tau ² = 0.00; •	Chi² = 2.9	8, df = 4	(P = 0.5	6); I ² = 0	%					
Test for overall effect: Z = 1.1	1 (P = 0.3	27)								
B. Above Knee										
Parmenter (RT Light)	25	155.8	7	34	96.1	3	4.0%	-0.06 [-1.41, 1.30]		
McGuigan (RT Mod-High)	63.5	94	11	9.3	12.2	9	8.7%	0.74 [-0.18, 1.65]		
McDermott (RT Mod)	94.9	105.4	46	14.7	93.3	20	24.9%	0.78 [0.23, 1.32]		
Parmenter (RT High)	112	59.9	7	34	96.1	4	4.2%	0.96 [-0.36, 2.29]		
Subtotal (95% CI)			71			36	41.7%	0.71 [0.29, 1.13]		
Heterogeneity: Tau ² = 0.00;	Chi ² = 1.4	4, df = 3 i	(P = 0.7)	0); I ² = 0	%					
Test for overall effect: Z = 3.3	31 (P = 0.)	0009)								
C. Whole Body										
Parmenter (RT Light)	-89	605	7	-88	439.2	3	4.0%	-0.00 [-1.35, 1.35]		
Parmenter (RT High)	275	578	7	-88	439.2	4	4.5%	0.62 [-0.65, 1.89]		
Subtotal (95% CI)			14			7	8.5%	0.33 [-0.60, 1.25]		
Heterogeneity: Tau ² = 0.00;	Chi ² = 0.4	3, df = 1	(P = 0.5	1); I ² = 0	%					
Test for overall effect: Z = 0.7	70 (P = 0	49)								
Total (95% CI)			165			84	100.0%	0.43 [0.16, 0.70]	•	
Heterogeneity: Tau ² = 0.00: (Chi² = 7.7	6. df = 10	(P = 0.)	65); I ^z =	0%					
Test for overall effect: Z = 3.12 (P = 0.002)										
Test for subgroup difference	s: Chi ² =	2.91. df=	2 (P = 1	0.23), I r	= 31.39	6			Favours control Favours R1	
						-				